NTAGI to discuss data of Gennova Pharma mRNA vaccine against COVID

The indigenous innovative mRNA vaccine is based on the second wave driven by the Delta variant and can be kept under 2 to 8 degrees Celsius this means vaccines can be stored between 2 and 8 degrees Celsius.;

Published On 2022-07-12 07:30 GMT | Update On 2022-07-12 07:30 GMT

New Delhi: The National Technical Advisory Group on Immunisation (NTAGI's) Covid working group is expected to conduct a meeting soon to discuss India's first mRNA vaccine against COVID and Biological E's Corbevax Booster dose for Covishield and Covaxin beneficiaries, said the sources on Monday.

Recently, the Drugs Controller General of India (DCGI) approved 2 dose mRNA vaccine of Gennova Biopharmaceuticals for COVID for restricted use in emergency situations for the above-18-years age group. It is the first time ever that this vaccine is stable for storage at 2 to 8 degrees Celsius.

Earlier, the Subject Expert Committee under India's drug regulator found that the data submitted by Gennova Biopharmaceuticals was satisfactory in the meeting held on Friday, sources present in the meeting told the media agency.

Gennova Biopharmaceuticals submitted the data in the month of April followed by additional data in the month of May.

Earlier last month, in an exclusive interview with the media agency, Dr Sanjay Singh, Chief Executive Officer and Whole-time Director, Gennova Biopharmaceuticals Ltd, said that the company is ready to roll out India's first mRNA vaccine in 72 hours after the government's permission.

"We are ready with the vaccine, hopefully as soon as the NTAGI gives us the permission and the government gives us the way out we are able to roll out within 72 hours," he said.

The mRNA vaccine produced by Gennova Biopharmaceuticals Ltd will be sold out under the brand name GEMCOVAC-19.

The company has the capacity to produce 200-300 million doses depending upon the need.

"At present, we can go to 200-300 million doses, we can produce depending upon the need, but this can be scaled up because this is the advantage of this technology. You don't need huge manufacturing plants," Dr Singh said.

On pricing of the vaccine Dr Singh said that the pricing of the vaccine hasn't been yet decided, but the company is in conversation with the government.

"The pricing of the vaccine hasn't been decided yet, it's under conversation with the government but it has to be competitive pricing," he said.

The indigenous innovative mRNA vaccine is based on the second wave driven by the Delta variant and can be kept under 2 to 8 degrees Celsius this means vaccines can be stored between 2 and 8 degrees Celsius. Most other vaccines have to be stored at sub-zero temperature.

"Due to logistic issues, mRNA vaccines haven't reached to the neediest one. We will try to do this, we are going towards different regions Latin America, Africa and Southeast Asia. So, that we can not only have vaccine supply but also have the joint manufacturing facilities in different regions," explained Dr Singh when asked about future plans and export of vaccines.

Article Source : ANI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment

2025-08-02 07:00 GMT

NTAGI to discuss data of Gennova Pharma mRNA vaccine against COVID

The indigenous innovative mRNA vaccine is based on the second wave driven by the Delta variant and can be kept under 2 to 8 degrees Celsius this means vaccines can be stored between 2 and 8 degrees Celsius.;

Similar News

Health Ministry Notifies Cosmetics Rules 2025, Empowers States To Suspend Licences

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray

CDSCO Panel Accepts Phase I Trial Data for Intas' Denosumab Biosimilar

Torrent Pharma: USFDA concludes inspection at Vizag facility with zero observations

Gilead Sciences gets USFDA nod for new Biktarvy indication for people with HIV who are treatment experienced, restarting antiretroviral treatment

USFDA issues 4 observations for Jubilant Generics Roorkee facility

Granules India arm gets 1 USFDA observation for Hyderabad facility

CDSCO Panel Clears PURE & CURE's Sickle Cell Trial With Conditions On Sample Size, Sites